KAIGENE
LIVE

Serial Number

99259208

Owner

Kaigene, Inc.

Attorney

Devon E. White

Filing Date

Jun 30, 2025

Add to watchlist:

No watchlists yet
View on USPTO

KAIGENE Trademark

Serial Number: 99259208

KAIGENE is a trademark filed by Kaigene, Inc. on June 30, 2025. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

Kaigene, Inc. (4 trademarks)

9808 Medical Center Dr. Suite #430
Rockville, MD 20850

Entity Type: 03

Trademark Details

Filing Date

June 30, 2025

Registration Date

Not Registered

Goods & Services

Research and development in the pharmaceutical and biotechnology fields; Medical and pharmaceutical research services in relation to protein degradation; Providing medical and scientific research information in the field of biochemical, therapeutic, and pharmaceutical preparations; Research and development of platform technology, namely, a biological platform for manufacturing therapeutics for the treatment of autoimmune diseases; Research and development of platform technology, namely, a platform for research and development of pharmaceuticals for the treatment of autoimmune diseases; Development of platform technology, namely, biotherapeutic platforms for use in manufacturing pharmaceuticals and therapeutics; Medical and scientific research, namely, conducting clinical trials for others; Laboratory research services relating to pharmaceuticals; Scientific and technological services, namely, research and design services in the field of process development, validation, qualification, and manufacturing of pharmaceuticals and biopharmaceuticals; Scientific and technological consultation services in the field of development, manufacturing and testing of pharmaceuticals and biopharmaceuticals; Providing product research and development in the pharmaceutical field for purposes of process development, validation, qualification, and manufacturing of pharmaceuticals and biopharmaceuticals; Custom development of pharmaceutical and biopharmaceutical products; Providing evaluation testing for pharmaceutical and biopharmaceutical products featuring protein degradation; Pre-clinical and non-clinical evaluation testing of pharmaceutical and biopharmaceutical products; Pharmaceutical and biopharmaceutical research and development featuring protein degradation for others; Pharmaceutical research for the treatment of immunological diseases, inflammatory diseases, neurological diseases, cancer, and other human diseases, and genetic disorders; Medical and pharmaceutical research in relation to targeted therapies that degrade disease driving membrane and extracellular proteins; Testing, inspection, research, or development of pharmaceutical preparations; Providing an on-line searchable database featuring protein molecules for scientific research purposes; Providing on-line non-downloadable software program for use in the discovery and development of targeted proteins used to develop treatments for diseases; Providing on-line non-downloadable software program for use in the discovery and development of targeted proteins used to develop medicines; Providing on-line non-downloadable software program for identifying, searching, and screening protein molecules; Providing on-line non-downloadable software program for searching within a library of protein molecules; Providing medical and scientific research information; Consulting services in the field of genetic science

Pharmaceutical and therapeutic preparations for the treatment of immunological diseases, inflammatory diseases, neurological diseases, cancer, and other human diseases, and genetic disorders; Pharmaceutical preparations, namely, a drug formulation using protein degradation for use in treating immunological diseases, inflammatory diseases, neurological diseases, cancer, and other human diseases, and genetic disorders; Pharmaceutical and therapeutic preparations for modulating protein degradation pathways; Biochemical preparations for medical use for the treatment of immunological diseases, inflammatory diseases, neurological diseases, cancer, and other human diseases, and genetic disorders; Pharmaceutical preparations for targeted protein degradation, comprising small molecules, peptides, biologics, antibodies designed for the treatment of immunological diseases, inflammatory diseases, neurological diseases, cancer, and other human diseases, and genetic disorders; Proteins, protein fragments, and protein conjugates all for use in the manufacture of pharmaceutical preparations for treatment of immunologic diseases, particularly autoimmune diseases

Chemical preparations for scientific purposes; Molecules for use in industry, namely, protein-modulating molecules for use in the pharmaceutical industry; Molecules for use in science, namely, protein-modulating molecules for use in the pharmaceutical industry; Molecules for molecular biology, other than for medical or veterinary use, namely, protein-modulating molecules for use in the pharmaceutical industry

Filing History

APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Feb 13, 2026 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Feb 13, 2026 XELR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Nov 19, 2025 GNRN
NON-FINAL ACTION E-MAILED
Nov 19, 2025 GNRT
NON-FINAL ACTION WRITTEN
Nov 19, 2025 CNRT
ASSIGNED TO EXAMINER
Nov 18, 2025 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Nov 4, 2025 NWOS
APPLICATION FILING RECEIPT MAILED
Jun 30, 2025 MAFR
NEW APPLICATION ENTERED
Jun 30, 2025 NWAP